All In Biotech

Drug Trial Radar · NCT07480733

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

410

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Nov 30, 2027

Study completion Nov 11, 2028

Sponsor

Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label Phase II clinical study. The primary objective is to evaluate the investigator-assessed objective response rate of JS212 and JS213 as monotherapy and in combination regimens in patients with advanced solid tumors. This study aims to explore the safety, tolerability, and preliminary efficacy of JS212, JS213, as well as JS212 in combination with JS213, toripalimab, and JS207.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

  • JS212 for InjectionDrug

    administered by intravenous infusion on Day 1 of each 21-day cycle.

  • JS213 for InjectionDrug

    administered by intravenous infusion on Day 1 of each 21-day cycle.

  • JS207 for InjectionDrug

    administered by intravenous infusion on Day 1 of each 21-day cycle.

  • ToripalimabDrug

    administered by intravenous infusion on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: up to 6 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.